Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $17.0 million.

  • Cytek Biosciences' Net Cash Flow rose 21561.48% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.2 million, marking a year-over-year decrease of 186866.65%. This contributed to the annual value of -$73.4 million for FY2024, which is 4370.94% up from last year.
  • As of Q3 2025, Cytek Biosciences' Net Cash Flow stood at $17.0 million, which was up 21561.48% from -$18.9 million recorded in Q2 2025.
  • Cytek Biosciences' Net Cash Flow's 5-year high stood at $216.9 million during Q3 2021, with a 5-year trough of -$166.0 million in Q1 2023.
  • For the 5-year period, Cytek Biosciences' Net Cash Flow averaged around -$3.9 million, with its median value being -$2.2 million (2025).
  • As far as peak fluctuations go, Cytek Biosciences' Net Cash Flow surged by 4311334.66% in 2021, and later tumbled by 865611.81% in 2023.
  • Cytek Biosciences' Net Cash Flow (Quarter) stood at -$12.8 million in 2021, then crashed by 219.7% to -$41.0 million in 2022, then surged by 111.76% to $4.8 million in 2023, then plummeted by 1449.0% to -$65.1 million in 2024, then soared by 126.07% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q3 2025, -$18.9 million for Q2 2025, and -$2.2 million during Q1 2025.